Recently, the National Copyright Administration officially released a report titled “China’s Copyright Protection and Development Status (2025)” in both Chinese and English. The report system summarizes
Current biopharmaceutical financing updates: MicroEye Medical has completed nearly 100 million yuan Series A, and clinical trials of ophthalmic surgical robots have come to an end;
With the official implementation of Order No. 818 (Regulations on the Management of Clinical Research and Clinical Translational Applications of Biomedical New Technologies), how overseas innovation
· EU Included in the “Special 301 Report” Watch List for the First Time Since 2006 · Switzerland's Patent Law Modernization Reform · Japan Patent Office
In this issue, we have selected and summarized ten heavyweight original achievements in cutting-edge scientific research, covering the mechanism of the association between arrhythmia and dementia,
This issue’s biopharmaceutical financing roundup covers cutting-edge tracks including AI-enabled RNA technology, in-vitro platelet regeneration, medical laser devices, microsurgical instruments, AI-powered interventional therapy, in-vivo gene editing,
The Symposium on Innovative Drug R&D Layout and Globalization Strategies amid International Competition concluded successfully on May 28. Centered on four core themes including innovative drug
· Hubei Issues Implementation Plan for Intellectual Property Administrative Protection · Fujian Releases Local Standard for Full - Chain Intellectual Property Public Services · 2026 Canadian
Recently, the National Medical Products Administration (NMPA) has approved the marketing of five innovative drugs, including Anituumab Injection, Sedomingji Injection, Luzunuole Sodium Tablets, Nicalimab Injection, and
As of January–April 2026, compared with the same period in 2025: The number of granted invention patents in China reached 295,178, a year-on-year increase of 10.16%.